Last updated: 2026-10-09 05:03:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Viking Therapeutics, Inc. (VKTX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $27,73, with a market capitalization of $3,61B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $25,77 to $43,15. This page covers its latest market performance, valuation, price trends and company information.
$3,61B | |
$28,37 | |
$99,41 | |
$0,88 | |
$28,54 | |
7,49M | |
4,06M | |
-- | |
$43,15 | |
$25,77 | |
-- | |
-- |
Viking Therapeutics, Inc. (VKTX) last closed at $28,54 as of 2026-10-08 23:59:00, unchanged from the previous close of $28,54.
During the latest regular trading session, VKTX traded between $0,88 and $99,41, with a volume of 7,49M shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Viking Therapeutics, Inc. (VKTX) moved from $31,81 to $27,73, representing a decline of 12,82% ($4,08).
The stock traded between $27,07 and $33,65 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 6,72 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 11,3%
VKTX is currently trading at $27,73, placing it 11,3% of the way from its 52-week low of $25,77 to its 52-week high of $43,15. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 65 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Viking Therapeutics, Inc. (VKTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.